Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
GYRE Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GYRE Stock 12 Month Forecast
Average Price Target
$18.00
▲(120.32% Upside)
| Highest Price Target$20.00 | Average Price Target$18.00 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$18
Buy
120.32%
Upside
Reiterated
10/15/25
Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset ValuationValuation and Risks. We reiterate our Buy rating and $18 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from Gyre’s lead asset, hydronidone in MASH and associated fibrosis (100% contribution; 20% PoS) in the U.S. Key areas of future potential upside are based on four main factors: 1) securing further partnership agreements to develop pipeline in both U.S. and ex-U.S.
Jefferies
$16
Buy
95.84%
Upside
Initiated
10/10/25
Noble Financial
$20
Buy
144.80%
Upside
Reiterated
09/09/25
Gyre Therapeutics (GYRE) Receives a Buy from Noble FinancialWe expect approval in 2H2026, followed by launch in FY2027. Hydronidone Phase 3 Showed Strong Efficacy. In addition to supporting approval, we view the Phase 3 trial for Hydronidone as proof-of-concept for its mechanism of action. The data supports the use of Hydronidone in other conditions leading to liver fibrosis. Several conditions leading to fibrosis have been tested, with a trial in MASH (Metabolic Dysfunction-Associated Steatohepatitis) planned in the US during 2H25. CEO Change Announced. Dr. Han Ying will be transitioning from CEO to Senior Vice President of Science, with responsibility over discovery and the product pipeline. Ping Yang, currently Executive Chairman, is now Interim CEO and will oversee company operations and expansion. Mr. Zhang has been on Gyre’s Board of Directors since January 2025 and was appointed Executive Chairman in March 2025.
Wedbush
$27
Buy
230.48%
Upside
Initiated
07/14/25
Stifel Nicolaus
$28
Buy
242.72%
Upside
Initiated
06/24/25
LifeSci Capital
$22
Buy
169.28%
Upside
Initiated
06/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$18
Buy
120.32%
Upside
Reiterated
10/15/25
Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset ValuationValuation and Risks. We reiterate our Buy rating and $18 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from Gyre’s lead asset, hydronidone in MASH and associated fibrosis (100% contribution; 20% PoS) in the U.S. Key areas of future potential upside are based on four main factors: 1) securing further partnership agreements to develop pipeline in both U.S. and ex-U.S.
Jefferies
$16
Buy
95.84%
Upside
Initiated
10/10/25
Noble Financial
$20
Buy
144.80%
Upside
Reiterated
09/09/25
Gyre Therapeutics (GYRE) Receives a Buy from Noble FinancialWe expect approval in 2H2026, followed by launch in FY2027. Hydronidone Phase 3 Showed Strong Efficacy. In addition to supporting approval, we view the Phase 3 trial for Hydronidone as proof-of-concept for its mechanism of action. The data supports the use of Hydronidone in other conditions leading to liver fibrosis. Several conditions leading to fibrosis have been tested, with a trial in MASH (Metabolic Dysfunction-Associated Steatohepatitis) planned in the US during 2H25. CEO Change Announced. Dr. Han Ying will be transitioning from CEO to Senior Vice President of Science, with responsibility over discovery and the product pipeline. Ping Yang, currently Executive Chairman, is now Interim CEO and will oversee company operations and expansion. Mr. Zhang has been on Gyre’s Board of Directors since January 2025 and was appointed Executive Chairman in March 2025.
Wedbush
$27
Buy
230.48%
Upside
Initiated
07/14/25
Stifel Nicolaus
$28
Buy
242.72%
Upside
Initiated
06/24/25
LifeSci Capital
$22
Buy
169.28%
Upside
Initiated
06/18/25
Best Analysts Covering Gyre Therapeutics
1 Month
xxx
Success Rate
1/3 ratings generated profit
Average Return
-1.37%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -1.37% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+3.50%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.50% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+3.50%
reiterated a buy rating 11 days ago
Copying Matthew Keller's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.50% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
+3.50%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +3.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GYRE Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
3
4
5
5
6
Buy
0
0
0
0
0
Hold
12
12
12
14
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
16
17
19
15
Each month's total comprises the sum of three months' worth of ratings.
GYRE Financial Forecast
GYRE Stock Forecast FAQ
What is GYRE’s average 12-month price target, according to analysts?
Based on analyst ratings, Gyre Therapeutics’s 12-month average price target is 18.00.
What is GYRE’s upside potential, based on the analysts’ average price target?
Gyre Therapeutics has 120.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GYRE a Buy, Sell or Hold?
Gyre Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Gyre Therapeutics’s price target?
The average price target for Gyre Therapeutics is 18.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 120.32% Increase from the current price of $8.17.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 120.32% Increase from the current price of $8.17.
What do analysts say about Gyre Therapeutics?
Gyre Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of GYRE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.